STOCK TITAN

Innovent Biologi - IVBIY STOCK NEWS

Welcome to our dedicated page for Innovent Biologi news (Ticker: IVBIY), a resource for investors and traders seeking the latest updates and insights on Innovent Biologi stock.

Company Overview

Innovent Biologics is a dynamic biopharmaceutical company that has established itself in the global market through its commitment to innovation and excellence. Founded with a mission to empower patients worldwide with affordable, high-quality medicines, Innovent focuses on developing cutting-edge therapies for major diseases including oncologic, autoimmune, cardiovascular and metabolic, and ophthalmologic conditions. Using advanced technologies and a targeted approach in precision medicine, Innovent has built a robust portfolio that features novel drug candidates and innovative formulations designed to address complex medical challenges.

Core Business Areas

At its core, Innovent is engaged in the research, development, manufacturing, and commercialization of innovative medicines. The company’s operations span from early-stage discovery to clinical development and regulatory review. With an extensive pipeline that leverages advancements in targeted therapies, immune checkpoint inhibitors, and antibody–drug conjugates, Innovent is well positioned to address unmet clinical needs. Its portfolio includes multiple therapeutic areas such as:

  • Oncology: Precision therapies that target key molecular pathways, focusing on cancers such as lung cancer, among others.
  • Autoimmune Diseases: Innovative biologics that modulate immune responses to provide relief for complex autoimmune conditions.
  • Cardiovascular and Metabolic Conditions: Developing treatments that help manage and improve patient outcomes in chronic health issues.
  • Ophthalmologic Diseases: Advancing therapies that address eye diseases with novel mechanisms of action.

Operational Expertise and Global Collaborations

Innovent’s success is bolstered by its extensive experience in clinical research and its strategic collaborations with over 30 global healthcare companies. This network enables the company to harness complementary expertise, optimize R&D processes, and expand its market reach. By partnering with leading global pharmaceutical companies, Innovent reinforces its commitment to scientific excellence and regulatory compliance, ensuring that its products meet high international standards while remaining accessible to patients worldwide.

Research and Development Excellence

Research and development form the backbone of Innovent’s operations. The company invests in a pipeline that reflects its commitment to addressing challenging diseases through innovative mechanisms, such as targeted therapies and novel biologic treatments. With multiple products in various clinical and regulatory stages, Innovent remains dedicated to advancing scientific knowledge and pioneering treatment alternatives. This is achieved through state-of-the-art research facilities, rigorous clinical trials, and continuous innovation in drug design and development.

Market Position and Industry Impact

Innovent Biologics has positioned itself as a significant entity within the global biopharmaceutical industry. Its integration of advanced technological platforms with strategic global partnerships ensures that it remains at the forefront of precision medicine. The company’s diverse and evolving product portfolio demonstrates its capacity to address both current and emerging health challenges. Investors and industry commentators recognize Innovent for its robust approach to research, its deep industry expertise, and its commitment to delivering accessible and effective therapies.

Commitment to Quality and Integrity

Innovent operates under a set of core principles that emphasize integrity, scientific rigor, and collaboration. The company’s motto, "Start with Integrity, Succeed through Action," reflects its ethos in adhering to high standards of industry practices. This commitment ensures that each product undergoes thorough evaluation and quality assessments, reinforcing its credibility and trustworthiness in the highly competitive biopharmaceutical landscape.

Investor Considerations

For investors seeking a comprehensive understanding of a company that leverages cutting-edge science to address complex health issues, Innovent Biologics represents a multifaceted business model. Its established record in clinical development, broad pipeline of innovative therapies, and strategic global collaborations provide a solid foundation of industry expertise and operational excellence. The detailed presentation of its diverse therapeutic segments and rigorous approach to drug development make Innovent a noteworthy subject for further research and analysis.

Rhea-AI Summary

Innovent Biologics (HKEX: 01801) has received Breakthrough Therapy Designation (BTD) from China's NMPA for IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, for treating unresectable locally advanced or metastatic mucosal or acral melanoma in treatment-naive patients.

Clinical trials involving 26 patients with advanced acral or mucosal melanoma demonstrated remarkable results, with an overall objective response rate (ORR) of 61.5% and a disease control rate (DCR) of 84.6%. These outcomes significantly exceed current domestic immunotherapy standards.

The company has initiated a pivotal study comparing IBI363 monotherapy versus pembrolizumab (Keytruda®). Additionally, IBI363 has secured two Fast Track Designations from the U.S. FDA for treating squamous non-small cell lung cancer and melanoma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Innovent Biologics (IVBIY) announces the presentation of preclinical data for multiple novel cancer therapeutics at the 2025 AACR Annual Meeting in Chicago from April 25-30. The presentations include data on several groundbreaking molecules:

- IAR037: A novel CD40/PD-L1 bispecific antibody for advanced solid tumors
- IBI3010: A FRα targeting biparatopic antibody-drug conjugate
- IBI3019: A first-in-class EGFR/CDH17/CD16A tri-specific antibody for colorectal cancer
- IBI3026: A novel anti-PD-1/IL-12 fusion protein
- IBI3014: A TROP2xPD-L1 bi-specific ADC

The company will also present findings on combination therapies involving olverembatinib with lisaftoclax for leukemia treatment. These presentations showcase Innovent's expanding technological capabilities in developing first-in-class bispecific antibodies, multi-specific antibodies, and ADCs for oncology applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.9%
Tags
conferences clinical trial
-
Rhea-AI Summary

Innovent Biologics announces historic 2024 results with its first-ever positive profit, reporting Non-IFRS profit of RMB331.6 million and EBITDA of RMB411.6 million. Total revenue reached RMB9,421.9 million, growing 51.8% year-over-year, with product sales revenue at RMB8,227.9 million (+43.6%).

The company expanded its portfolio to 15 approved products, including new launches in oncology and chronic diseases. Key products include Dovbleron® (ROS1 inhibitor), Limertinib (EGFR TKI), and Jaypirca® (BTK inhibitor). The company achieved an 84.9% gross profit margin and reduced S,G&A expenses ratio by 7.1 percentage points.

Innovent targets RMB20bn product revenue by 2027 and aims to advance five pipeline assets to global MRCT Phase 3 stage by 2030. The company maintains strong financial position with RMB10,221.1 million in cash and short-term assets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Innovent Biologics (HKEX: 01801) has initiated dosing in a Phase 3 clinical trial (HeriCare-Ovarian01) of IBI354, a HER2 ADC, for platinum-resistant ovarian cancer (PROC). The study will compare IBI354 against standard chemotherapy, focusing on progression-free survival and overall survival as primary endpoints.

Previous Phase 1/2 results showed promising outcomes with IBI354:

  • 40.2% overall objective response rate (ORR) and 81.6% disease control rate (DCR) across 87 PROC patients
  • 52.5% ORR and 90.0% DCR in 40 patients treated with 12mg/kg dose
  • 55.6% ORR and 88.9% DCR in HER2 IHC 1+ subjects at 12mg/kg

The drug demonstrated a favorable safety profile with 21.5% grade 3+ treatment-related adverse events, low discontinuation rates (1.6%), and no treatment-related deaths. Common side effects included nausea, decreased white blood cell count, and anemia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.9%
Tags
-
Rhea-AI Summary

Innovent Biologics (IVBIY) and HUTCHMED have announced positive results from their FRUSICA-2 Phase 2/3 clinical trial, evaluating sintilimab combined with fruquintinib as second-line treatment for advanced renal cell carcinoma (RCC) in China.

The study met its primary endpoint of progression-free survival (PFS) and showed improvements in secondary endpoints, including objective response rate (ORR) and duration of response (DoR). The trial compared the combination therapy against axitinib or everolimus monotherapy for second-line RCC treatment.

The combination has previously received conditional approval from China's NMPA for treating advanced endometrial cancer with pMMR tumors based on the FRUSICA-1 study. The companies plan to proceed with NDA filings in the coming months, aiming to make this treatment option available to patients who have progressed on previous therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Innovent Biologics has received NMPA approval for SYCUME® (teprotumumab N01), China's first and world's second IGF-1R antibody drug for treating thyroid eye disease (TED). This breakthrough ends a 70-year period without new TED treatments in China.

TED, an autoimmune disorder affecting orbital health, has an annual incidence of 16 per 100,000 in women and 2.9 per 100,000 in men. The Phase 3 RESTORE-1 study demonstrated that 85.8% of patients achieved ≥2 mm proptosis reduction at Week 24 with SYCUME® treatment.

SYCUME® offers advantages including a liquid injection formation, improved stability, and better patient compliance. This approval provides a more accessible treatment option compared to the existing IGF-1R antibody treatment available overseas, which costs approximately 3 million RMB per course.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Innovent Biologics (IVBIY) has initiated a pivotal study of IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, comparing it head-to-head with pembrolizumab in melanoma patients. The first patient has been dosed in this registrational trial for treating unresectable locally advanced or metastatic mucosal or acral melanoma in treatment-naive patients.

Early clinical trials of IBI363 showed promising results:

  • 61.5% overall objective response rate (ORR)
  • 84.6% disease control rate (DCR)
  • Sustained tumor responses and long-term benefits observed

The safety profile has been manageable, with common treatment-related adverse events including arthralgia, anemia, thyroid dysfunction, and rash. The study's primary endpoint is progression-free survival (PFS), assessed by an Independent Radiology Review Committee using RECIST v1.1 criteria.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Innovent Biologics announces that its ipilimumab injection (IBI310) has received NDA acceptance and Priority Review designation from China's NMPA. The application is for combination use with sintilimab as neoadjuvant treatment for resectable MSI-H/dMMR colon cancer, marking China's first domestic CTLA-4 inhibitor NDA.

The approval is based on the Phase 3 NeoShot trial results, which met its primary endpoint. In the per-protocol population (n=101), the combination therapy showed significantly higher pathological complete response rates (80.0% vs 47.7%, p=0.0007) compared to sintilimab alone. All patients achieved R0 resection, with no disease recurrence at 5.65 months median follow-up.

The treatment could increase R0 resection rates, achieve pathological complete response, and potentially reduce the need for adjuvant chemotherapy without increasing safety risks or surgery delays.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Innovent Biologics announced that its PD-1/IL-2α-bias bispecific antibody fusion protein, IBI363, received its second Fast Track Designation from the FDA for treating advanced squamous non-small cell lung cancer (sqNSCLC) that has progressed after anti-PD-(L)1 therapy and chemotherapy.

Clinical trial results presented at WCLC 2024 showed promising efficacy: the 3 mg/kg dose group (n=18) achieved 50.0% objective response rate (ORR) and 88.9% disease control rate (DCR). The 1/1.5 mg/kg group showed 5.5 months median progression-free survival (PFS) with 30.7% 12-month PFS rate. Notably, IBI363 demonstrated effectiveness in both PD-L1 low and high expression populations, with ORRs of 36.4% and 31.8% respectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Innovent Biologics and ASK Pharm announce NMPA approval of limertinib, their third-generation EGFR TKI drug for treating adult patients with locally advanced or metastatic EGFR T790M-mutated non-small cell lung cancer (NSCLC). This marks Innovent's 14th commercial product.

A Phase 2b pivotal study with 301 patients showed impressive results: 68.8% overall response rate, 92.4% disease control rate, and 11.0 months median progression-free survival. For patients with CNS lesions, the response rate was 65.9% with 10.6 months median PFS.

Additionally, limertinib met its primary endpoint in a Phase 3 trial comparing it to gefitinib for first-line NSCLC treatment. A separate NDA for first-line treatment in patients with specific EGFR mutations is under NMPA review.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Innovent Biologi (IVBIY)?

The current stock price of Innovent Biologi (IVBIY) is $22.294 as of March 31, 2025.

What is the market cap of Innovent Biologi (IVBIY)?

The market cap of Innovent Biologi (IVBIY) is approximately 8.0B.

What is Innovent Biologics’ core business?

Innovent Biologics is dedicated to discovering, developing, manufacturing and commercializing innovative medicines. It focuses on critical areas such as oncology, autoimmune disorders, cardiovascular and metabolic diseases, and ophthalmologic conditions.

Which therapeutic areas does Innovent target?

The company targets multiple therapeutic areas, including oncology with its precision therapies, autoimmune diseases through novel biologics, cardiovascular and metabolic conditions, and ophthalmologic diseases with advanced treatment options.

How does Innovent generate revenue?

Innovent generates revenue primarily through the commercialization of its innovative drug portfolio. This includes revenue from partnerships, licensing agreements, and direct product sales as its therapies gain market approval.

What role do global collaborations play in Innovent's strategy?

Global collaborations are key to Innovent's strategy. The company partners with over 30 leading healthcare organizations to enhance its research, accelerate clinical development, and expand its market reach, ensuring high-quality products and regulatory excellence.

What distinguishes Innovent in the competitive biopharmaceutical landscape?

Innovent is distinguished by its commitment to precision medicine, a robust and diversified pipeline, strategic global partnerships, and a proven track record in rigorous R&D and quality manufacturing.

How does Innovent approach research and development?

Innovent places heavy emphasis on R&D, investing in cutting-edge technologies and clinical trials. Its diverse pipeline and innovative drug development strategies underscore its comprehensive approach to addressing complex unmet medical needs.

Who are the likely beneficiaries of Innovent's therapies?

Patients suffering from complex and intractable diseases such as various cancers, autoimmune conditions, and cardiovascular and metabolic diseases are the primary beneficiaries of Innovent's innovative, high-quality therapies.

What is the significance of the company's quality and regulatory focus?

Innovent's strict adherence to high industry standards and regulatory requirements ensures that its products are scientifically sound, safe, and effective. This focus on quality reinforces trust and credibility among healthcare professionals and investors.
Innovent Biologi

OTC:IVBIY

IVBIY Rankings

IVBIY Stock Data

7.97B
91.64M
Biotechnology
Healthcare
Link
China
Suzhou